Company
LON:AZN
AstraZeneca is one of the world's leading pharmaceutical companies, with a broad range of medicines designed to fight disease. AstraZeneca has over 67,000 empolyees and operates in over 100 countries with growing presence in important emerging markets.
1084 stories · page 36 of 55
Orphan drug status gives drugmakers certain benefits in order to encourage them to develop treatments for rare diseases which might otherwise lack sufficient profit motive
2019 will be an important year for the firm with the re-start of Phase I/IIa trial for RXC004, part of a niche, and potentially breakthrough group of cancer drugs
Arix is investing US$11mln in VelosBio through a Series A funding round in return for an 11.2% stake in the company
Archive
A glance at some of the day's highlights from the Proactive Investors newswire
Circassia promotes AstraZeneca’s Tudorza COPD drug in the US in return for a share of the profits, while it also has the commercial rights to another COPD drug made by AstraZeneca called Duaklir
The pound is off 0.52% against the greenback at the time of writing..
A total of 17,000 people with type-2 diabetes took part in the study
In clinical trials, 75% of the people taking the drug responded to it. In 30% of cases, Lumoxiti had a “complete durable” effect
Companies are putting together contingency plans should they not be able to move their goods freely around Europe post-Brexit
A breakthrough therapy designation is designed to expedite the development and review of medicines that are intended to treat a serious and have shown promise in early-stage clinical trials
Only one new lupus treatment has been approved in the last 60 years, so today’s news won’t come as a surprise to many scientists and doctors
“Today's approval of Bydureon BCise will enable us to offer an additional treatment option for patients with type-2 diabetes whose blood sugar levels are inadequately controlled by other glucose-lowering medicines together with diet and exe
Jefferies cut its rating on AstraZeneca to ‘hold’ from ‘buy’ but raised its target price to 6,200p from 5,942p
JPMorgan’s analysts said the target hike comes after their updated their numbers to make “further upgrades to new launch trajectories, and include risk-adjusted forecasts for three further pipeline shots on goal”
Archive
The day ahead sees Cineworld and Legal & General report their first-half results
Archive
Aside from HSBC's numbers, Prudential, L&G, Standard Life Aberdeen, and Hargreaves Lansdown are all on the results docket in the coming week
A look at some of the biggest risers and fallers in London on Thursday
The drugs giant's oncology division grew revenues by 42%
The Nasdaq on Wall Street is down over 88 points at the time of writing, at 7,420.
Archive
Three of the 10 largest London-listed companies (by capitalisation) are updating the market on Thursday. A dozen or more other household names are also expected to report.
